Commonwealth Equity Services LLC Buys 373 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Commonwealth Equity Services LLC grew its stake in shares of Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS – Free Report ) by 1.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission.

The fund owned 21,826 shares of the company’s stock after buying an additional 373 shares during the period. Commonwealth Equity Services LLC’s holdings in Ionis Pharmaceuticals were worth $763,000 as of its most recent filing with the Securities and Exchange Commission. Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company.



Geode Capital Management LLC raised its holdings in Ionis Pharmaceuticals by 7.4% in the third quarter. Geode Capital Management LLC now owns 2,668,358 shares of the company’s stock worth $106,922,000 after purchasing an additional 183,814 shares during the period.

Assenagon Asset Management S.A. increased its position in shares of Ionis Pharmaceuticals by 967.

2% in the 4th quarter. Assenagon Asset Management S.A.

now owns 141,917 shares of the company’s stock valued at $4,961,000 after buying an additional 128,619 shares in the last quarter. SG Americas Securities LLC raised its stake in Ionis Pharmaceuticals by 222.5% during the 4th quarter.

SG Americas Securities LLC now owns 23,927 shares of the company’s stock worth $836,000 after buying an additional 16,508 shares during the period. Jacobs Levy Equity Management Inc. lifted its holdings in Ionis Pharmaceuticals by 13.

6% during the third quarter. Jacobs Levy Equity Management Inc. now owns 650,779 shares of the company’s stock worth $26,070,000 after acquiring an additional 77,909 shares in the last quarter.

Finally, Groupama Asset Managment grew its stake in Ionis Pharmaceuticals by 4.1% in the third quarter. Groupama Asset Managment now owns 916,060 shares of the company’s stock valued at $367,000 after acquiring an additional 36,084 shares during the period.

Institutional investors own 93.86% of the company’s stock. Insider Activity In other Ionis Pharmaceuticals news, EVP Eric Swayze sold 7,154 shares of the business’s stock in a transaction on Thursday, January 16th.

The stock was sold at an average price of $32.84, for a total value of $234,937.36.

Following the transaction, the executive vice president now owns 45,670 shares of the company’s stock, valued at approximately $1,499,802.80. The trade was a 13.

54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link . Also, CEO Brett P.

Monia sold 33,445 shares of Ionis Pharmaceuticals stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $32.63, for a total value of $1,091,310.

35. Following the sale, the chief executive officer now owns 207,396 shares in the company, valued at $6,767,331.48.

The trade was a 13.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here .

Insiders sold a total of 111,956 shares of company stock worth $3,608,439 over the last quarter. Insiders own 2.71% of the company’s stock.

Wall Street Analysts Forecast Growth Get Our Latest Stock Report on IONS Ionis Pharmaceuticals Stock Up 5.3 % Shares of NASDAQ IONS opened at $28.71 on Thursday.

The firm has a market cap of $4.56 billion, a PE ratio of -9.44 and a beta of 0.

28. The company’s fifty day simple moving average is $32.32 and its 200 day simple moving average is $35.

47. The company has a quick ratio of 8.82, a current ratio of 8.

47 and a debt-to-equity ratio of 2.12. Ionis Pharmaceuticals, Inc.

has a 12-month low of $27.00 and a 12-month high of $52.34.

Ionis Pharmaceuticals ( NASDAQ:IONS – Get Free Report ) last issued its earnings results on Wednesday, February 19th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.

12) by $0.46. The company had revenue of $227.

00 million for the quarter, compared to analysts’ expectations of $140.97 million. Ionis Pharmaceuticals had a negative return on equity of 100.

05% and a negative net margin of 64.25%. Ionis Pharmaceuticals’s quarterly revenue was down 30.

2% compared to the same quarter last year. During the same period last year, the business earned $0.12 EPS.

As a group, sell-side analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.

About Ionis Pharmaceuticals ( Free Report ) Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. Further Reading Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.

com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS – Free Report ). Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.

com's FREE daily email newsletter ..